Fresenius Medical Care : Adapting to reality –excluding governmental relief from estimates
>FY 2022 due 22 February - labour shortage to impact last quarter - Q4 revenues of € 5,011m (+7.9% y-o-y) should be driven by organic growth of 1.8%, external growth of 40bp and forex tailwind of 570bp. The North American business remains challenging on the back of labour shortages and is expected to decline organically by 0.6%. Q4 EBIT of € 360m (-19.9% y-o-y, margin 7.2% suffers from negative operating leverage, higher personnel costs as well as from FME25-related ...RegistrarFresenius Medical Care is a kidney dialysis company, operating in both the field of dialysis services and the field of dialysis products for the treatment of end-stage renal disease (ESRD). Co.'s dialysis business is vertically integrated, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. In addition, Co. sells dialysis products to other dialysis service providers. In the U.S.A., Co. also provides inpatient dialysis services and other services under contract to hospitals. Co. provides patient services, including renal pharmaceutical products and in the U.S.A., laboratory services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.